An open-label, randomized, 3-way crossover study to assess the effect of Colesevelam HCl (WelcholA) 3750 mg on the single dose pharmacokinetics of Glipizide ER 20 mg in healthy human adult subjects

Trial Profile

An open-label, randomized, 3-way crossover study to assess the effect of Colesevelam HCl (WelcholA) 3750 mg on the single dose pharmacokinetics of Glipizide ER 20 mg in healthy human adult subjects

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Colesevelam (Primary) ; Glipizide
  • Indications Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 09 Dec 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India.
    • 10 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by Clinical Trials Registry - India.
    • 13 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top